Intratesticular Androgens and Spermatogenesis During Severe Gonadotropin Suppression Induced by Male Hormonal Contraceptive Treatment
- 10 September 2007
- journal article
- research article
- Published by Wiley in Journal of Andrology
- Vol. 28 (5) , 734-741
- https://doi.org/10.2164/jandrol.107.002790
Abstract
Male hormonal contraceptive regimens function by suppressing gonadotropin secretion, resulting in a dramatic decrease in testicular androgen biosynthesis and spermatogenesis. Animal studies suggest that persistent intratesticular (iT)‐androgen production has a stimulatory effect on spermatogenesis in the setting of gonadotropin suppression. We hypothesized that men with incompletely suppressed spermatogenesis (>1 000 000 sperm/mL) during male hormonal contraceptive treatment would have higher iT‐androgen concentrations than men who achieved severe oligospermia (≤1 000 000 sperm/mL). Twenty healthy men ages 18–55 years enrolled in a 6‐month male contraceptive study of transdermal testosterone (T) gel (100 mg/d) plus depomedroxyprogesterone acetate (300 mg intramuscularly every 12 weeks) with or without the gonadotropin releasing hormone (GnRH) antagonist acyline (300 μg/kg subcutaneously every 2 weeks for 12 weeks) were studied. During the 24th week of treatment, subjects underwent fine needle aspirations of the testes and iT‐T and iT‐dihydrotestosterone (iT‐DHT) were measured in testicular fluid by liquid chromatography—tandem mass spectrometry. All men dramatically suppressed spermatogenesis; 15 of 20 men were severely oligospermic, and 5 of 20 suppressed to 1.5 million −3.2 million sperm per milliliter. In all subjects, mean iT‐T and iT‐DHT concentrations were 35 ± 8 and 5.1 ± 0.8 nmol/L. IT‐androgen concentrations did not significantly differ in men who did and did not achieve severe oligospermia (P = .41 for iT‐T; P = .18 for iT‐DHT). Furthermore, there was no significant correlation between iT‐T or iT‐DHT and sperm concentration after 24 weeks of treatment. In this study of prolonged gonadotropin suppression induced by male hormonal contraceptive treatment, differences in iT‐androgens did not explain differences in spermatogenesis. Additional studies to identify factors involved in persistent spermatogenesis despite gonadotropin suppression are warranted.Keywords
This publication has 37 references indexed in Scilit:
- Elevated End‐of‐Treatment Serum INSL3 Is Associated With Failure to Completely Suppress Spermatogenesis in Men Receiving Male Hormonal ContraceptionJournal of Andrology, 2007
- Drug Insight: recent advances in male hormonal contraceptionNature Clinical Practice Endocrinology & Metabolism, 2006
- Simultaneous determination of steroid composition of human testicular fluid using liquid chromatography tandem mass spectrometrySteroids, 2004
- Luteinizing Hormone Receptor-Mediated Effects on Initiation of Spermatogenesis in Gonadotropin-Deficient (hpg) Mice Are Replicated by Testosterone1Biology of Reproduction, 2004
- Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperaturePublished by Elsevier ,2003
- Efficacy and acceptability of testosterone implants, alone or in combination with a 5α-reductase inhibitor, for male hormonal contraceptionContraception, 2000
- Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha- reductase activity in oligozoospermic men administered supraphysiological doses of testosteroneJournal of Clinical Endocrinology & Metabolism, 1996
- Induction of spermatogenesis by androgens in gonadotropin-deficient (hpg) miceEndocrinology, 1995
- Exogenously administered testosterone maintains spermatogenesis quantitatively in adult rats actively immunized against gonadotropin- releasing hormoneEndocrinology, 1992
- Re-evaluation of the intratesticular level of testosterone required for quantitative maintenance of spermatogenesis in the ratJournal of Endocrinology, 1988